Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 7/20 | 0.77 |
| ▸ | KDR | P35968 | 7/20 | 0.77 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.56 |
| ▸ | CHEK2 | O96017 | 3/20 | 0.55 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.55 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.49 |
| ▸ | SGK1 | O00141 | 1/20 | 0.49 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.49 |
| ▸ | USP7 | Q93009 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | FYN | P06241 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17668204 | 0.88 | PDGFRB (0.69) | PDGFRBKDRMAP4K4CHEK2FYN | |
| SCHEMBL29994102 | 0.87 | PDGFRB (0.61) | PDGFRBKDRCHEK2MKNK1NEK1 | |
| SCHEMBL21994688 | 0.87 | PDGFRB (0.61) | PDGFRBKDRCHEK2MKNK1NEK1 | |
| SCHEMBL17668133 | 0.87 | KDR (1.00) | PDGFRBKDR | |
| SCHEMBL3351243 | 0.85 | MAP4K4 (0.59) | PDGFRBKDRMAP4K4CHEK2USP7 | |
| SCHEMBL11709594 | 0.84 | PDGFRB (0.56) | PDGFRBKDREGFRNEK1SGK1 | |
| SCHEMBL17111526 | 0.81 | PDGFRB (0.53) | PDGFRBKDREGFRTSHR | |
| SCHEMBL27602501 | 0.78 | PDGFRB (0.54) | PDGFRBKDRTSHR | |
| SCHEMBL29041952 | 0.77 | PDGFRB (0.56) | PDGFRBKDRMAP4K4CHEK2MKNK1 | |
| SCHEMBL30508324 | 0.77 | PDGFRB (0.56) | PDGFRBKDRMAP4K4CHEK2MKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220033396-A1 | FURTHER HETEROAROMATIC COMPOUNDS HAVING ACTIVITY AGAINST RSV | Janssen Sciences Ireland Unlimited Company (IE) | 2022-02-03 | — | — | US | disclosed |
| CN-113166146-A | Other heteroaromatic compounds with anti-RSV activity | 爱尔兰詹森科学公司 | 2021-07-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220033396-A1 | FURTHER HETEROAROMATIC COMPOUNDS HAVING ACTIVITY AGAINST RSV | VIM, MAVS, VARS1 | PDGFRB 1655/4885KDR 2001/4885MAP4K4 3079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.